While nearly 40 million people in the US suffer from diabetes, some 8.7 million of them don’t even know they have the ...
New ICD-10 diagnosis code is for patients with history of type 2 diabetes who bring blood sugar levels to a non-diabetic range below 6.5% for at least 3 months.
Keystone Health will host a free Diabetes Health Fair on Saturday, November 15, 2025, from 9 a.m. to 12 p.m. at Keystone ...
Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...
The FDA has accepted for review the sBLA for Afrezza (insulin human) inhalation powder in children and adolescents with type 1 or 2 diabetes.
The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...
Eli Lilly announces positive results from phase 3 ACHIEVE-2 & ACHIEVE-5 trials of orforglipron versus dapagliflozin in adults with type 2 diabetes: Indianapolis Thursday, October ...
The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...
Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...
A diabetes diet is a healthy eating plan that helps control your blood sugar. Here are the best foods to eat, no matter what type of diabetes you have.
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback